שווי פעילות לרווח לפני ריבית, מסים ופחת Azitra, Inc. (AZTR)

Azitra, Inc. (AZTR) relies on a staff of leading microbiologists and dermatozoon experts, expanding its team with clinical trial specialists. The company is developing innovative treatments for eczema, targeting the vast biotechnology market. The share price history based on the EV/EBITDA metric currently stands at 0.00. The business's financial stability is secured through the patenting of unique bacterial platforms for the therapy of chronic skin pathologies.

This indicator compares Enterprise Value (EV) with EBITDA, allowing for an asset valuation that accounts for debt load. For Azitra, Inc. (AZTR), which is striving for a monopoly in skin bioengineering, an EV/EBITDA ratio including depreciation and debt at 0.00 reflects capitalization efficiency amidst the clinical race. Analysis of this chart helps determine the extent to which the issuer is undervalued relative to US industry benchmarks.